Unichem Laboratories working capital

Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
351.16×351.16×357.83×365.18×405.94×
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
133.23×133.23×120.10×128.35×147.31×
135.76×135.76×148.32×162.02×156.98×
348.63×348.63×329.61×331.51×396.27×
1.76×1.68×2.03×1.73×1.42×
0.60×0.60×0.63×0.54×0.41×
0.01×0.01×−0.05×−0.24×0.42×
0.02×0.02×−0.03×0.17×1.87×
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

UNICHEMLAB₹488.80

Unichem Laboratories Limited

· Pharma & Health
₹ CrorePeersGUFICBIORPGLIFEGUJTHEMSMSPHARMAORCHPHARMAINDSWFTLABSOLARAFDCMcap ₹3,441 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)405.94365.18357.83351.16351.16
Receivable Days (DSO)147.31128.35120.10133.23133.23
Payable Days (DPO)156.98162.02148.32135.76135.76
Cash Conversion Cycle (days)396.27331.51329.61348.63348.63
Working Capital Turnover1.421.732.031.681.76
Asset Turnover0.410.540.630.600.60
Cash Conversion (CFO/Net Income)0.42-0.24-0.050.010.01
CFO/EBITDA1.870.17-0.030.020.02
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.